Webinars
Webinar: advancing cardiac safety integrating new ICH E14/S7b Q&As best practices into in vivo dog QT assay with Biotrial, UCB and Boehringer Ingelheim
“Advancing Cardiac Safety: Integrating New ICH E14/S7B Q&As Best Practices into In Vivo Dog QT Assay“
Date : November 7th
Time: 10:00 am (EST)
Recent evolution in E14/S7B guidelines expectations pave the way for a simpler and more powerful proarrhythmia risk assessments, with a true integration of preclinical and clinical data.
With more than 35 years of experience, Biotrial has developed significant expertise in translational research, bridging the gap between preclinical and clinical services. This vast experience guarantees high-quality, reliable, and innovative solutions in cardiac safety assessments, establishing Biotrial as an industry leader.
Agenda
- Understanding ICH E14/S7B Q&As Guidelines
- Case study: pharmacological and statistical sensitivity of the in vivo dog QT assay
in line with ICH E14/S7B Q&As - Integrated Preclinical and Clinical proarrhythmia risk assessment
Speakers
- Eric Martel, Laboratory Head, Senior Principal Scientist General Pharmacology at Boehringer Ingelheim
- Jean-Pierre Valentin, Senior Director, Head of Investigate Toxicology at UCB
- Eric Delpy, Scientific Director at Biotrial
- Mathieu Grace, Biometrics and Core Lab Product Manager at Biotrial
